MeCo Diagnostics and CNIO Publish Immunotherapy Study
MeCo Diagnostics and CNIO have published a study in the Journal of Clinical Investigation, revealing that osteopontin drives resistance to immunotherapy in breast cancer. This study builds on previous research linking antifibrotic therapy with reduced recurrence risk in high MeCo Score tumors, suggesting a combined strategy for better outcomes in aggressive breast cancer.
New discovery connects antifibrotic therapy and immunotherapy in aggressive breast cancer
SAN DIEGO, CA, UNITED STATES, July 23, 2026 /EINPresswire.com/ — MeCo Diagnostics and long-time collaborators at the Spanish National Cancer Research Centre (CNIO …